Uptravi

Active Ingredient(s): Selexipag
FDA Approved: * December 21, 2015
Pharm Company: * ACTELION PHARMS LTD
Category: Blood Pressure

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Uptravi Overview

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[1] ACT-333679 or MRE-269, the active metabolite of selexipag Contents 1 Contraindications 2 Adverse effects 3 History 4 See also 5 References Contraindicatio...

Read more Uptravi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Selexipag

Recent Uptravi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Selexipag
  • Tablet: 0.2mg, 0.4mg, 0.6mg, 0.8mg, 1.2mg, 1.4mg, 1.6mg, 1000mcg, 1200mcg, 1400mcg, 1600mcg, 1mg, 200mcg, 400mcg, 600mcg, 800mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Uptravi: (8 results)

Sorted by National Drug Code
  • 66215-602 Uptravi 200 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-604 Uptravi 400 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-606 Uptravi 600 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-608 Uptravi 800 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-610 Uptravi 1000 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-612 Uptravi 1200 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-614 Uptravi 1400 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-616 Uptravi 1600 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Selexipag or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 February 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA